Our new design is here! Clearer, more modern, more international. With our new design and visual language we have achieved a strong visual alignment with the corporate identity of Revvity, Inc. At the same time, we harmonized the visual appearance of the Euroimmun and IDS brands creating a new modernized look which visually reflects our shared identity and growing collaboration. But what really counts remains the same: our […]
Long anticipated – now available: the neurology portfolio for the UNIQO 160, our all-in-one automated IFA system, has been expanded by nine more indirect immunofluorescence assays (IFA). While the previous portfolio primarily contained classic Euroimmun BIOCHIP Mosaics with different tissue sections as substrates, these new additions are highly relevant monospecific IFA with a particular focus
A newly published international study has demonstrated the high sensitivity of the Euroimmun Dermal Binder Mosaic 1 for detecting antibodies against laminin β4, laminin 332 and collagen type VII. The prospective multicentre study represents the latest milestone in a long-standing research collaboration between Euroimmun and the University of Lübeck, Germany. Shedding light on anti-laminin β4
The way we learn has changed dramatically in recent years. During the pandemic, online training became essential, and now, we’re taking the next big step to make learning smarter and more efficient. We are proud to announce the launch of Euroimmun Campus, our brand-new Learning Management System (LMS). Think of it as a modern, intuitive
A collaboration driving discovery A long-standing research collaboration between Euroimmun and the University of Lübeck, Germany has led to major advances in understanding anti-p200 pemphigoid, a rare autoimmune skin blistering disease. Recent publications from the collaborative team have identified laminin subunit beta 4 (laminin β4) as a key autoantigen, demonstrated the pathogenic effects of anti-laminin
Currently, dengue fever poses the greatest challenge in terms of arbovirus infections. With over 14 million cases reported worldwide in 2024, this is the largest ever recorded epidemic of vector-borne viral diseases [1]. In Europe, 304 autochthonous cases were registered in the same year, representing a significant increase compared to 130 cases in 2023 and
